123 related articles for article (PubMed ID: 32556179)
21. BAY 80-6946 is a highly selective intravenous PI3K inhibitor with potent p110α and p110δ activities in tumor cell lines and xenograft models.
Liu N; Rowley BR; Bull CO; Schneider C; Haegebarth A; Schatz CA; Fracasso PR; Wilkie DP; Hentemann M; Wilhelm SM; Scott WJ; Mumberg D; Ziegelbauer K
Mol Cancer Ther; 2013 Nov; 12(11):2319-30. PubMed ID: 24170767
[TBL] [Abstract][Full Text] [Related]
22. The Selective Phosphoinoside-3-Kinase p110δ Inhibitor IPI-3063 Potently Suppresses B Cell Survival, Proliferation, and Differentiation.
Chiu H; Mallya S; Nguyen P; Mai A; Jackson LV; Winkler DG; DiNitto JP; Brophy EE; McGovern K; Kutok JL; Fruman DA
Front Immunol; 2017; 8():747. PubMed ID: 28713374
[TBL] [Abstract][Full Text] [Related]
23. Inactivation of PI(3)K p110δ breaks regulatory T-cell-mediated immune tolerance to cancer.
Ali K; Soond DR; Pineiro R; Hagemann T; Pearce W; Lim EL; Bouabe H; Scudamore CL; Hancox T; Maecker H; Friedman L; Turner M; Okkenhaug K; Vanhaesebroeck B
Nature; 2014 Jun; 510(7505):407-411. PubMed ID: 24919154
[TBL] [Abstract][Full Text] [Related]
24. Impact of somatic PI3K pathway and ERBB family mutations on pathological complete response (pCR) in HER2-positive breast cancer patients who received neoadjuvant HER2-targeted therapies.
Toomey S; Eustace AJ; Fay J; Sheehan KM; Carr A; Milewska M; Madden SF; Teiserskiene A; Kay EW; O'Donovan N; Gallagher W; Grogan L; Breathnach O; Walshe J; Kelly C; Moulton B; Kennedy MJ; Gullo G; Hill AD; Power C; Duke D; Hambly N; Crown J; Hennessy BT
Breast Cancer Res; 2017 Jul; 19(1):87. PubMed ID: 28750640
[TBL] [Abstract][Full Text] [Related]
25. The Role of p110δ in the Development and Activation of B Lymphocytes.
Newman R; Turner M
Adv Exp Med Biol; 2015; 850():119-35. PubMed ID: 26324350
[TBL] [Abstract][Full Text] [Related]
26. VEGF-mediated PI3K class IA and PKC signaling in cardiomyogenesis and vasculogenesis of mouse embryonic stem cells.
Bekhite MM; Finkensieper A; Binas S; Müller J; Wetzker R; Figulla HR; Sauer H; Wartenberg M
J Cell Sci; 2011 Jun; 124(Pt 11):1819-30. PubMed ID: 21540297
[TBL] [Abstract][Full Text] [Related]
27. Potency and pharmacokinetics of broad spectrum and isoform-specific p110γ and δ inhibitors in cancers.
Setti A; Kumar MJ; Babu KR; Rasagna A; Prasanna MG; Devi TA; Pawar SC
J Recept Signal Transduct Res; 2016; 36(1):26-36. PubMed ID: 26791581
[TBL] [Abstract][Full Text] [Related]
28. Recent patents of gene sequences relative to the phosphatidylinositol 3-kinase/Akt pathway and their relevance to drug discovery.
Doepfner KT; Boller D; De Laurentiis A; Guerreiro AS; Marinov M; Arcaro A
Recent Pat DNA Gene Seq; 2007; 1(1):9-23. PubMed ID: 19075915
[TBL] [Abstract][Full Text] [Related]
29. PI3K in cancer: its structure, activation modes and role in shaping tumor microenvironment.
Liu X; Xu Y; Zhou Q; Chen M; Zhang Y; Liang H; Zhao J; Zhong W; Wang M
Future Oncol; 2018 Mar; 14(7):665-674. PubMed ID: 29219001
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of class IA PI3K enzymes in non-small cell lung cancer cells uncovers functional compensation among isoforms.
Stamatkin C; Ratermann KL; Overley CW; Black EP
Cancer Biol Ther; 2015; 16(9):1341-52. PubMed ID: 26176612
[TBL] [Abstract][Full Text] [Related]
31. p110δ phosphoinositide 3-kinase represses IgE switch by potentiating BCL6 expression.
Zhang TT; Makondo KJ; Marshall AJ
J Immunol; 2012 Apr; 188(8):3700-8. PubMed ID: 22422878
[TBL] [Abstract][Full Text] [Related]
32. PI3K p110β isoform synergizes with JNK in the regulation of glioblastoma cell proliferation and migration through Akt and FAK inhibition.
Zhao HF; Wang J; Jiang HR; Chen ZP; To SS
J Exp Clin Cancer Res; 2016 May; 35():78. PubMed ID: 27176481
[TBL] [Abstract][Full Text] [Related]
33. Gene of the month: PIK3CA.
Lai K; Killingsworth MC; Lee CS
J Clin Pathol; 2015 Apr; 68(4):253-7. PubMed ID: 25688137
[TBL] [Abstract][Full Text] [Related]
34. A selective inhibitor of the p110delta isoform of PI 3-kinase inhibits AML cell proliferation and survival and increases the cytotoxic effects of VP16.
Billottet C; Grandage VL; Gale RE; Quattropani A; Rommel C; Vanhaesebroeck B; Khwaja A
Oncogene; 2006 Oct; 25(50):6648-59. PubMed ID: 16702948
[TBL] [Abstract][Full Text] [Related]
35. Targeting phosphoinositide 3-kinase: moving towards therapy.
Marone R; Cmiljanovic V; Giese B; Wymann MP
Biochim Biophys Acta; 2008 Jan; 1784(1):159-85. PubMed ID: 17997386
[TBL] [Abstract][Full Text] [Related]
36. P110delta, a novel phosphoinositide 3-kinase in leukocytes.
Vanhaesebroeck B; Welham MJ; Kotani K; Stein R; Warne PH; Zvelebil MJ; Higashi K; Volinia S; Downward J; Waterfield MD
Proc Natl Acad Sci U S A; 1997 Apr; 94(9):4330-5. PubMed ID: 9113989
[TBL] [Abstract][Full Text] [Related]
37. PI3Kinase-p110δ Overexpression Impairs Dendritic Morphogenesis and Increases Dendritic Spine Density.
Hood VL; Paterson C; Law AJ
Front Mol Neurosci; 2020; 13():29. PubMed ID: 32180704
[TBL] [Abstract][Full Text] [Related]
38. Phosphatidylinositol 3 kinase (PI3K) inhibitors as new weapon to combat cancer.
Elmenier FM; Lasheen DS; Abouzid KAM
Eur J Med Chem; 2019 Dec; 183():111718. PubMed ID: 31581005
[TBL] [Abstract][Full Text] [Related]
39. Quinazoline based small molecule exerts potent tumour suppressive properties by inhibiting PI3K/Akt/FoxO3a signalling in experimental colon cancer.
Qazi AK; Hussain A; Khan S; Aga MA; Behl A; Ali S; Singh SK; Taneja SC; Shah BA; Saxena AK; Mondhe DM; Hamid A
Cancer Lett; 2015 Apr; 359(1):47-56. PubMed ID: 25554016
[TBL] [Abstract][Full Text] [Related]
40. Isoform-specific phosphoinositide 3-kinase inhibitors exert distinct effects in solid tumors.
Edgar KA; Wallin JJ; Berry M; Lee LB; Prior WW; Sampath D; Friedman LS; Belvin M
Cancer Res; 2010 Feb; 70(3):1164-72. PubMed ID: 20103642
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
